Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.
Identifieur interne : 000C25 ( Main/Exploration ); précédent : 000C24; suivant : 000C26Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.
Auteurs : Jiwon Choi [Corée du Sud] ; Mi-Gyeong Kim [Corée du Sud] ; Yu-Kyoung Oh [Corée du Sud] ; Young Bong Kim [Corée du Sud]Source :
- Expert opinion on therapeutic patents [ 1744-7674 ] ; 2017.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Animaux, Anticorps neutralisants (immunologie), Brevets comme sujet, Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie), Humains, Infections à coronavirus (), Infections à coronavirus (immunologie), Lymphocytes T (immunologie), Souris, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie).
- MESH :
- administration et posologie : Adjuvants immunologiques, Vaccins antiviraux.
- immunologie : Anticorps neutralisants, Coronavirus du syndrome respiratoire du Moyen-Orient, Infections à coronavirus, Lymphocytes T, Vaccins antiviraux.
- Animaux, Brevets comme sujet, Humains, Infections à coronavirus, Souris.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Animals, Antibodies, Neutralizing (immunology), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Humans, Mice, Middle East Respiratory Syndrome Coronavirus (immunology), Patents as Topic, T-Lymphocytes (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Viral Vaccines.
- chemical , immunology : Antibodies, Neutralizing, Viral Vaccines.
- immunology : Coronavirus Infections, Middle East Respiratory Syndrome Coronavirus, T-Lymphocytes.
- prevention & control : Coronavirus Infections.
- Animals, Humans, Mice, Patents as Topic.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) has emerged as a new pathogen, causing severe complications and a high case fatality rate. No direct treatments are available as yet, highlighting the importance of prevention through suitable vaccination regimes. The viral spike (S) protein has been characterized as a key target antigen for vaccines. In particular, S protein domains have been utilized to produce high titers of neutralizing antibodies. Areas covered: Since the first report of MERS-CoV infection, a limited number of MERS-CoV-specific patents have been filed. Patents related to MERS-CoV are categorized into three areas: treatments, antibodies, and vaccines (receptor-related). This review mainly focuses on the types and efficacies of vaccines, briefly covering treatments and antibodies against the virus. MERS-CoV vaccine forms and delivery systems, together with comparable development strategies against SARS-CoV are additionally addressed. Expert opinion: Vaccines must be combined with delivery systems, administration routes, and adjuvants to maximize T-cell responses as well as neutralizing antibody production. High immune responses require further study in animal models, such as human receptor-expressing mice, non-human primates, and camels. Such a consideration of integrated actions should contribute to the rapid development of vaccines against MERS-CoV and related coronaviruses.
DOI: 10.1080/13543776.2017.1281248
PubMed: 28121202
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E05
- to stream PubMed, to step Curation: 000E05
- to stream PubMed, to step Checkpoint: 000B62
- to stream Ncbi, to step Merge: 001925
- to stream Ncbi, to step Curation: 001925
- to stream Ncbi, to step Checkpoint: 001925
- to stream Main, to step Merge: 000C28
- to stream Main, to step Curation: 000C25
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.</title><author><name sortKey="Choi, Jiwon" sort="Choi, Jiwon" uniqKey="Choi J" first="Jiwon" last="Choi">Jiwon Choi</name><affiliation wicri:level="1"><nlm:affiliation>a College of Animal Bioscience & Technology , Konkuk University , Seoul , Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>a College of Animal Bioscience & Technology , Konkuk University , Seoul </wicri:regionArea><wicri:noRegion>Seoul </wicri:noRegion></affiliation></author><author><name sortKey="Kim, Mi Gyeong" sort="Kim, Mi Gyeong" uniqKey="Kim M" first="Mi-Gyeong" last="Kim">Mi-Gyeong Kim</name><affiliation wicri:level="1"><nlm:affiliation>b College of Pharmacy , Seoul National University , Seoul , Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>b College of Pharmacy , Seoul National University , Seoul </wicri:regionArea><wicri:noRegion>Seoul </wicri:noRegion></affiliation></author><author><name sortKey="Oh, Yu Kyoung" sort="Oh, Yu Kyoung" uniqKey="Oh Y" first="Yu-Kyoung" last="Oh">Yu-Kyoung Oh</name><affiliation wicri:level="1"><nlm:affiliation>b College of Pharmacy , Seoul National University , Seoul , Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>b College of Pharmacy , Seoul National University , Seoul </wicri:regionArea><wicri:noRegion>Seoul </wicri:noRegion></affiliation></author><author><name sortKey="Kim, Young Bong" sort="Kim, Young Bong" uniqKey="Kim Y" first="Young Bong" last="Kim">Young Bong Kim</name><affiliation wicri:level="1"><nlm:affiliation>a College of Animal Bioscience & Technology , Konkuk University , Seoul , Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>a College of Animal Bioscience & Technology , Konkuk University , Seoul </wicri:regionArea><wicri:noRegion>Seoul </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28121202</idno><idno type="pmid">28121202</idno><idno type="doi">10.1080/13543776.2017.1281248</idno><idno type="wicri:Area/PubMed/Corpus">000E05</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E05</idno><idno type="wicri:Area/PubMed/Curation">000E05</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E05</idno><idno type="wicri:Area/PubMed/Checkpoint">000B62</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B62</idno><idno type="wicri:Area/Ncbi/Merge">001925</idno><idno type="wicri:Area/Ncbi/Curation">001925</idno><idno type="wicri:Area/Ncbi/Checkpoint">001925</idno><idno type="wicri:Area/Main/Merge">000C28</idno><idno type="wicri:Area/Main/Curation">000C25</idno><idno type="wicri:Area/Main/Exploration">000C25</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.</title><author><name sortKey="Choi, Jiwon" sort="Choi, Jiwon" uniqKey="Choi J" first="Jiwon" last="Choi">Jiwon Choi</name><affiliation wicri:level="1"><nlm:affiliation>a College of Animal Bioscience & Technology , Konkuk University , Seoul , Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>a College of Animal Bioscience & Technology , Konkuk University , Seoul </wicri:regionArea><wicri:noRegion>Seoul </wicri:noRegion></affiliation></author><author><name sortKey="Kim, Mi Gyeong" sort="Kim, Mi Gyeong" uniqKey="Kim M" first="Mi-Gyeong" last="Kim">Mi-Gyeong Kim</name><affiliation wicri:level="1"><nlm:affiliation>b College of Pharmacy , Seoul National University , Seoul , Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>b College of Pharmacy , Seoul National University , Seoul </wicri:regionArea><wicri:noRegion>Seoul </wicri:noRegion></affiliation></author><author><name sortKey="Oh, Yu Kyoung" sort="Oh, Yu Kyoung" uniqKey="Oh Y" first="Yu-Kyoung" last="Oh">Yu-Kyoung Oh</name><affiliation wicri:level="1"><nlm:affiliation>b College of Pharmacy , Seoul National University , Seoul , Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>b College of Pharmacy , Seoul National University , Seoul </wicri:regionArea><wicri:noRegion>Seoul </wicri:noRegion></affiliation></author><author><name sortKey="Kim, Young Bong" sort="Kim, Young Bong" uniqKey="Kim Y" first="Young Bong" last="Kim">Young Bong Kim</name><affiliation wicri:level="1"><nlm:affiliation>a College of Animal Bioscience & Technology , Konkuk University , Seoul , Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>a College of Animal Bioscience & Technology , Konkuk University , Seoul </wicri:regionArea><wicri:noRegion>Seoul </wicri:noRegion></affiliation></author></analytic><series><title level="j">Expert opinion on therapeutic patents</title><idno type="eISSN">1744-7674</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Animals</term><term>Antibodies, Neutralizing (immunology)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (prevention & control)</term><term>Humans</term><term>Mice</term><term>Middle East Respiratory Syndrome Coronavirus (immunology)</term><term>Patents as Topic</term><term>T-Lymphocytes (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Animaux</term><term>Anticorps neutralisants (immunologie)</term><term>Brevets comme sujet</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term><term>Humains</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (immunologie)</term><term>Lymphocytes T (immunologie)</term><term>Souris</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps neutralisants</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Infections à coronavirus</term><term>Lymphocytes T</term><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Middle East Respiratory Syndrome Coronavirus</term><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Mice</term><term>Patents as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Brevets comme sujet</term><term>Humains</term><term>Infections à coronavirus</term><term>Souris</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Middle East respiratory syndrome coronavirus (MERS-CoV) has emerged as a new pathogen, causing severe complications and a high case fatality rate. No direct treatments are available as yet, highlighting the importance of prevention through suitable vaccination regimes. The viral spike (S) protein has been characterized as a key target antigen for vaccines. In particular, S protein domains have been utilized to produce high titers of neutralizing antibodies. Areas covered: Since the first report of MERS-CoV infection, a limited number of MERS-CoV-specific patents have been filed. Patents related to MERS-CoV are categorized into three areas: treatments, antibodies, and vaccines (receptor-related). This review mainly focuses on the types and efficacies of vaccines, briefly covering treatments and antibodies against the virus. MERS-CoV vaccine forms and delivery systems, together with comparable development strategies against SARS-CoV are additionally addressed. Expert opinion: Vaccines must be combined with delivery systems, administration routes, and adjuvants to maximize T-cell responses as well as neutralizing antibody production. High immune responses require further study in animal models, such as human receptor-expressing mice, non-human primates, and camels. Such a consideration of integrated actions should contribute to the rapid development of vaccines against MERS-CoV and related coronaviruses.</div></front></TEI><affiliations><list><country><li>Corée du Sud</li></country></list><tree><country name="Corée du Sud"><noRegion><name sortKey="Choi, Jiwon" sort="Choi, Jiwon" uniqKey="Choi J" first="Jiwon" last="Choi">Jiwon Choi</name></noRegion><name sortKey="Kim, Mi Gyeong" sort="Kim, Mi Gyeong" uniqKey="Kim M" first="Mi-Gyeong" last="Kim">Mi-Gyeong Kim</name><name sortKey="Kim, Young Bong" sort="Kim, Young Bong" uniqKey="Kim Y" first="Young Bong" last="Kim">Young Bong Kim</name><name sortKey="Oh, Yu Kyoung" sort="Oh, Yu Kyoung" uniqKey="Oh Y" first="Yu-Kyoung" last="Oh">Yu-Kyoung Oh</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28121202
|texte= Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28121202" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |